Q-omics provides the consensus-scored ATXN2-AS profile across patient tissues and cancer cell-line models. ATXN2-AS expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATXN2-AS is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ATXN2-AS RNA expression shows 13,152 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where ATXN2-AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATXN2-AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATXN2-AS survival associations across molecular data types. ATXN2-AS RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATXN2-AS RNA expression–survival associations across cancer types. High ATXN2-AS expression shows unfavorable associations in KIRC, SKCM and MESO, but favorable associations in UCS, HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATXN2-AS RNA expression.
This table summarizes ATXN2-AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ATXN2-AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATXN2-AS shows higher tumor expression in COAD, LIHC, BLCA, HNSC, STAD and BRCA. The COAD box plot shows higher ATXN2-AS RNA expression in tumor versus normal tissue (log2 FC = +0.693, t-test p < 0.001).
This table shows molecular features associated with ATXN2-AS in patient tissues and cancer cell lines. In patient samples, ATXN2-AS shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
